GlutathioneAntioxidant & Detoxification PeptideSafety Rating 8/10

TypeTripeptide (γ-Glu-Cys-Gly)
CAS70-18-8
MW307.32 g/mol
Primary research areaAntioxidant / glutathione research

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose range600–1400 mg IV per dose (Parkinson's trials)source ↗
AdministrationIV infusion (typically over 10–30 minutes)
Half-life~10 minutes (plasma)
Safety8/10 · FDA-approved (oral/IV forms)
NCAA D1Permitted

Price Comparison

Compare vendors · per 600mg

15 vendors competing

VendorPrice$ / mgUpdated
Petratide ScienceBest $/mgCOA ✓ · 3P$44.95$0.0300May 14, 2026Buy →
Puratek PeptidesCOA ✓ · 3P$46.76$51.95−10% · code PEPTIDEPRICES$0.0312May 19, 2026Buy →
PureRawzCOA ✓ · 3P$109.84$0.0458May 14, 2026Buy →
Apex Peptide SupplyCOA ✓ · 3P$68.99$0.0460May 14, 2026Buy →
Ascension PeptidesCOA ✓ · 3POut of stock$75.00$149.99−50% · code peptidepri$0.0500Apr 16, 2026Buy →

Overview

About Glutathione

Mechanism of action

Master endogenous antioxidant; neutralizes reactive oxygen species (ROS); regenerates vitamins C and E; supports liver detoxification (Phase II); modulates immune response.

Safety profile

Generally very safe. IV: rare hypersensitivity. High-dose long-term: possible zinc depletion, theoretical melanin suppression. · Endogenous antioxidant; very safe; rare allergic reactions; widely used in IV wellness

Storage

Stability & handling

❄️Lyophilized (powder)−20°Cprotected from light
💉Reconstituted2–8°Cuse promptly
📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Related pages

More on Glutathione

Stack & Compare

Frequently Researched Together

Research

Studies & key findings

  • The landmark Sechi et al. (1996) open-label study in 9 early Parkinson's patients treated with IV glutathione 600 mg twice daily for 30 days reported a ~42% average decline in disability scores, with benefits persisting 2–4 months post-treatment — results that remain unreplicated in larger controlled trials.
  • A subsequent randomized, double-blind, placebo-controlled pilot trial (Hauser et al., 2009; 21 patients) found no significant difference in UPDRS motor scores between IV glutathione 1,400 mg three-times-weekly and placebo, though a trend toward mild symptomatic benefit was noted.

8 peer-reviewed sources cited — clinical, preclinical, and regulatory.

Read full research →
Failed to fetch